Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Loncastuximab Tesirine BLA Receives Priority Review in China for Relapsed/Refractory DLBCL

July 24th 2023

The China National Medical Products Administration has accepted and granted priority review to the biologics license application seeking the approval of loncastuximab tesirine-lpyl for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma following at least 2 prior lines of systemic therapy.

CHMP Advises Against Adagrasib Approval for KRAS G12C–Mutant Advanced NSCLC

July 24th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the conditional marketing authorization application for adagrasib for the treatment of patients with KRAS G12C–mutated advanced non–small cell lung cancer.

JZP458 Receives CHMP Recommendation for Approval in ALL, Lymphoblastic Lymphoma

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of JZP458 for use in combination with multi-agent chemotherapy for the treatment of adult and pediatric patients 1 month and older with acute lymphoblastic leukemia and lymphoblastic lymphoma who developed hypersensitivity or silent inactivation to Escherichia coli–derived asparaginase.

CHMP Supports Approval of Pembrolizumab Plus Trastuzumab/Chemotherapy for HER2+, PD-L1+ Advanced Gastric/GEJ Cancer

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors have a PD-L1 combined positive score of at least 1.

CB-010 Elicits 94% ORR in Relapsed/Refractory Non-Hodgkin Lymphoma

July 18th 2023

The allogeneic CAR T-cell therapy CB-010 demonstrated early signs of durable antitumor activity and favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Amivantamab Plus Chemotherapy Improves PFS in EGFR Exon 20–Mutant NSCLC

July 17th 2023

Amivantamab-vmjw plus carboplatin and pemetrexed led to a clinically meaningful and statistically significant improvement in progression-free survival vs carboplatin and pemetrexed alone in patients with newly diagnosed advanced or metastatic EGFR exon 20 insertion–mutated non–small cell lung cancer.

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14th 2023

Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14th 2023

Neoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

DKN-01 Plus Bevacizumab/Chemotherapy Advances to Part B in DeFianCe Trial in Advanced CRC

July 13th 2023

Leap Therapeutics has launched the randomized, controlled part B of the phase 2 DeFianCe trial, which will evaluate DKN-01 in combination with bevacizumab and chemotherapy as second-line therapy in patients with advanced colorectal cancer.

Dr Kilburn on Findings From the FIREFLY-1 Trial of Tovorafenib in Pediatric Low-Grade Glioma

July 10th 2023

Lindsay Kilburn, MD, discusses key efficacy findings from the phase 2 FIREFLY-1 trial of the investigational type II RAF inhibitor tovorafenib (DAY101) in heavily pretreated pediatric patients with low-grade glioma.

ONC-392/BNT316 Elicits Clinical Activity in Checkpoint Inhibitor–Resistant NSCLC

July 2nd 2023

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

Durvalumab Plus Tremelimumab Elicits Clinically Meaningful, 4-Year OS Advantage in Advanced HCC

June 30th 2023

Durvalumab plus a single priming dose of tremelimumab led to continued clinically meaningful overall survival benefit at 4 years compared with sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma not eligible for localized therapy.

European Commission Grants Orphan Drug Designation to Temferon for Glioma

June 30th 2023

The European Commission has granted an orphan drug designation to Temferon for the treatment of patients with glioma, joining glioblastoma multiforme in its designation.

NOX-A12 Plus Bevacizumab and Radiotherapy Shows Sustained Survival in Glioblastoma

June 29th 2023

The addition of the CXCL12 inhibitor NOX-A12 to standard frontline therapy with radiation and bevacizumab led to an overall survival rate of 83% at a median follow-up of 15 months in patients with glioblastoma.

FDA Grants Orphan Drug Designation to VCN-01 for Pancreatic Cancer

June 28th 2023

The FDA has granted an orphan drug designation to VCN-01, a systemic, selective, stroma-degrading oncolytic adenovirus for the treatment of patients with pancreatic cancer.

NKX101 Demonstrates Early Activity in Relapsed/Refractory AML

June 27th 2023

Treatment with NKX101 led to a best composite complete response rate of 67% in patients with relapsed/refractory acute myeloid leukemia, according to updated data from a dose-expansion cohort of an ongoing phase 1 trial.

FDA Approves Iopromide Injection for Contrast-Enhanced Mammography

June 26th 2023

The FDA has approved the first and only iodine-based contrast agent iopromide-300, -370 injection for intra-arterial and intravenous contrast-enhanced mammography.

FDA Grants Orphan Drug Designation to ERAS-801 for Malignant Glioma

June 23rd 2023

The FDA has granted an orphan drug designation to the orally bioavailable, reversible small molecule EGFR inhibitor ERAS-801 for the treatment of patients with malignant glioma, including glioblastoma.

NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

June 23rd 2023

Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma, including patients with disease progression after transplant or CAR T-cell therapy, and as a category 2A preferred regimen for patients with histologic transformation of indolent lymphoma to DLBCL with no intention to proceed to transplant, including patients with disease progression after transplant or CAR T-cell therapy.

Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit in Treatment-Naïve CLL

June 22nd 2023

Fixed-duration therapy with venetoclax plus obinutuzumab led to 60% reduction in the risk of progression or death compared with chlorambucil plus obinutuzumab, with benefit seen regardless of TP53 or IGHV mutation status, in previously untreated patients with chronic lymphocytic leukemia.